Cyagen Biosciences

Executive Summary

Cyagen Biosciences is a well-established contract research organization (CRO) based in Santa Clara, California, specializing in custom genetically engineered animal models, cell lines, and preclinical research services. Founded in 2006, the company supports academic, biotech, and pharmaceutical partners in translating research into investigational new drug (IND) applications. Its offerings include custom mouse and rat models, humanized systems, cell line engineering, and viral vector packaging. With a strong focus on genetic engineering and cell therapy, Cyagen has built a reputation for high-quality, customizable solutions that accelerate drug discovery and development. As a private company in the pre-clinical stage, Cyagen benefits from the growing demand for specialized preclinical models, particularly in immuno-oncology and gene therapy. The company's long operational history and established client base position it as a reliable partner in the competitive CRO landscape, though its private status limits visibility into financial performance and specific growth metrics.

Upcoming Catalysts (preview)

• Q3 2026Launch of Next-Generation Humanized Mouse Models70% success
• Q4 2026Strategic Partnership with Major Biopharma for Cell Therapy Services60% success
• Q2 2027Expansion of Viral Vector Manufacturing Capacity80% success